Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C153314
http://purl.obolibrary.org/obo/NCIT_C153314
|
|---|---|
| Preferred Name | Guretolimod |
| Definitions |
A synthetic, small molecule, toll-like receptor (TLR) 7 agonist, with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, guretolimod activates TLR7, resulting in type I interferon secretion and activation of cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses. TLR7 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A synthetic, small molecule, toll-like receptor (TLR) 7 agonist, with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, guretolimod activates TLR7, resulting in type I interferon secretion and activation of cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses. TLR7 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity. |
|---|---|
| prefLabel | Guretolimod
|
| label | Guretolimod
|
| NCI_META_CUI | CL554427
|
| PDQ_Closed_Trial_Search_ID | 794076
|
| code | C153314
|
| Has_Target | |
| prefixIRI | NCIT:C153314
|
| in_subset |
See more
See less
|
| Display_Name | Guretolimod
|
| Preferred_Name | Guretolimod
|
| FDA_UNII_Code | 2UG29YVL56
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Toll-like Receptor 7 Agonist DSP-0509
|
| CAS_Registry | 1488364-57-3
|
| NCI_Drug_Dictionary_ID | 794076
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 794076
|
| Semantic_Type | Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |